Can lenvatinib help shrink tumors?

Lenvatinib , an oral multikinase inhibitor, has been widely used in the treatment of malignant tumors. Through its unique mechanism of action, lenvatinib (lenvatinib) often reduces or stabilizes tumor size during treatment.

The primary efficacy of lenvatinib is due to its inhibitory effect on angiogenesis. It can effectively inhibit the activity of multiple key kinases such as vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR). This inhibitory effect blocks the formation of new blood vessels inside the tumor, thereby weakening the tumor's blood supply. When a tumor lacks adequate blood supply, it will experience ischemia, hypoxia, and even necrosis, which directly leads to a reduction in tumor size.

Lenvatinib also works by inhibiting tumor cell proliferation. It can inhibit the growth and division of tumor cells by interfering with the proliferation signaling pathways of tumor cells, such as FGFR and PDGFR. This inhibitory effect reduces the number of tumor cells, thereby promoting the reduction of tumor size.

In addition to the above two mechanisms,Lenvatinib (Lenvatinib) can also induce tumor cell apoptosis. It promotes the self-destruction of tumor cells by regulating signaling pathways related to apoptosis, such as PI3K/AKT and MAPK. This process also contributed to the reduction in tumor size.

In general,Lenvatinib (Lenvatinib) works together through multiple pathways to effectively inhibit the growth of tumors and promote their size reduction. However, due to individual differences, tumor types, and treatment options, the therapeutic effects of lenvatinib will vary. Therefore, when using this drug for treatment, it is necessary to pay close attention to the patient's condition changes and treatment response in order to adjust the treatment plan in a timely manner and ensure the safety and effectiveness of the treatment.